Midazolam
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Midazolam |
| DrugBank ID | DB00683 |
| Brand Names (EU) | Buccolam |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.74% |
Approved Indication (EMA)
Treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults.BUCCOLAM must only be used by parents/carers where the patient has been diagnosed to have epilepsy.For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. See section 4.2.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | insomnia (disease) | 99.74% | DL |
| 2 | anxiety | 99.35% | DL |
| 3 | myofascial pain syndrome | 97.92% | DL |
| 4 | obsessive-compulsive disorder | 95.69% | DL |
| 5 | tendinitis | 93.55% | DL |
| 6 | benign paroxysmal torticollis of infancy | 93.49% | DL |
| 7 | anxiety disorder | 92.83% | DL |
| 8 | agoraphobia | 92.75% | DL |
| 9 | myositis fibrosa | 92.52% | DL |
| 10 | idiopathic granulomatous myositis | 92.52% | DL |
| 11 | dysthymic disorder | 92.01% | DL |
| 12 | paranoid personality disorder | 91.95% | DL |
| 13 | histrionic personality disorder (disease) | 91.95% | DL |
| 14 | schizotypal personality disorder | 91.95% | DL |
| 15 | schizoid personality disorder | 91.95% | DL |
| 16 | fibromyalgia | 88.87% | DL |
| 17 | sleep disorder, initiating and maintaining sleep | 88.58% | DL |
| 18 | Asperger syndrome | 87.93% | DL |
| 19 | inclusion body myositis | 83.12% | DL |
| 20 | attention deficit-hyperactivity disorder | 81.19% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.